259 related articles for article (PubMed ID: 28801607)
21. [Cisplatin promotes PD-L1 expression in A549 human lung adenocarcinoma cells via activating the ERK pathway].
Zhu H; Liu D; Deng S
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2021 Oct; 37(10):891-896. PubMed ID: 34670665
[TBL] [Abstract][Full Text] [Related]
22. HGF/c-MET pathway contributes to cisplatin-mediated PD-L1 expression in hepatocellular carcinoma.
Zhang ZS; Yang RH; Yao X; Cheng YY; Shi HX; Yao CY; Gao ZX; Qi DF; Zhang WK; Dou YY; Guo J; Hu MW; Zhao H; Fang D
Cell Biol Int; 2021 Dec; 45(12):2521-2533. PubMed ID: 34486197
[TBL] [Abstract][Full Text] [Related]
23. Tumour cell-intrinsic CTLA4 regulates PD-L1 expression in non-small cell lung cancer.
Zhang H; Dutta P; Liu J; Sabri N; Song Y; Li WX; Li J
J Cell Mol Med; 2019 Jan; 23(1):535-542. PubMed ID: 30378264
[TBL] [Abstract][Full Text] [Related]
24. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
Wang H; Fu C; Du J; Wang H; He R; Yin X; Li H; Li X; Wang H; Li K; Zheng L; Liu Z; Qiu Y
J Exp Clin Cancer Res; 2020 Feb; 39(1):29. PubMed ID: 32024543
[TBL] [Abstract][Full Text] [Related]
25. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
[TBL] [Abstract][Full Text] [Related]
26. Cisplatin treatment increases stemness through upregulation of hypoxia-inducible factors by interleukin-6 in non-small cell lung cancer.
Zhang F; Duan S; Tsai Y; Keng PC; Chen Y; Lee SO; Chen Y
Cancer Sci; 2016 Jun; 107(6):746-54. PubMed ID: 27009878
[TBL] [Abstract][Full Text] [Related]
27. PD-1/PD-L1 enhanced cisplatin resistance in gastric cancer through PI3K/AKT mediated P-gp expression.
Wu L; Cai S; Deng Y; Zhang Z; Zhou X; Su Y; Xu D
Int Immunopharmacol; 2021 May; 94():107443. PubMed ID: 33581579
[TBL] [Abstract][Full Text] [Related]
28. Cisplatin contributes to programmed death-ligand 1 expression in bladder cancer through ERK1/2-AP-1 signaling pathway.
Tsai TF; Lin JF; Lin YC; Chou KY; Chen HE; Ho CY; Chen PC; Hwang TI
Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31341011
[TBL] [Abstract][Full Text] [Related]
29. PD-L1 Mediates Dysfunction in Activated PD-1
Concha-Benavente F; Kansy B; Moskovitz J; Moy J; Chandran U; Ferris RL
Cancer Immunol Res; 2018 Dec; 6(12):1548-1560. PubMed ID: 30282672
[TBL] [Abstract][Full Text] [Related]
30. αVEGFR2-MICA fusion antibodies enhance immunotherapy effect and synergize with PD-1 blockade.
Pan M; Wang F; Nan L; Yang S; Qi J; Xie J; Shao S; Zou H; Wang M; Sun F; Zhang J
Cancer Immunol Immunother; 2023 Apr; 72(4):969-984. PubMed ID: 36227341
[TBL] [Abstract][Full Text] [Related]
31. Preclinical Evaluation of Off-The-Shelf PD-L1+ Human Natural Killer Cells Secreting IL15 to Treat Non-Small Cell Lung Cancer.
Lu T; Ma R; Mansour AG; Bustillos C; Li Z; Li Z; Ma S; Teng KY; Chen H; Zhang J; Villalona-Calero MA; Caligiuri MA; Yu J
Cancer Immunol Res; 2024 Jun; 12(6):731-743. PubMed ID: 38572955
[TBL] [Abstract][Full Text] [Related]
32. The Mechanism of Anti-PD-L1 Antibody Efficacy against PD-L1-Negative Tumors Identifies NK Cells Expressing PD-L1 as a Cytolytic Effector.
Dong W; Wu X; Ma S; Wang Y; Nalin AP; Zhu Z; Zhang J; Benson DM; He K; Caligiuri MA; Yu J
Cancer Discov; 2019 Oct; 9(10):1422-1437. PubMed ID: 31340937
[TBL] [Abstract][Full Text] [Related]
33. Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases.
Dhupkar P; Gordon N; Stewart J; Kleinerman ES
Cancer Med; 2018 Jun; 7(6):2654-2664. PubMed ID: 29733528
[TBL] [Abstract][Full Text] [Related]
34. A CRISPR activation screen identifies MUC-21 as critical for resistance to NK and T cell-mediated cytotoxicity.
Lee DH; Ahn H; Sim HI; Choi E; Choi S; Jo Y; Yun B; Song HK; Oh SJ; Denda-Nagai K; Park CS; Irimura T; Park Y; Jin HS
J Exp Clin Cancer Res; 2023 Oct; 42(1):272. PubMed ID: 37858248
[TBL] [Abstract][Full Text] [Related]
35. An inhibitor of programmed death ligand 1 enhances natural killer cell-mediated immunity against malignant melanoma cells.
Lee YS; Heo W; Choi HJ; Cho HR; Nam JH; Ki YG; Lee HR; Son WC; Park YS; Kang CD; Bae J
PLoS One; 2021; 16(4):e0248870. PubMed ID: 33793576
[TBL] [Abstract][Full Text] [Related]
36. Cisplatin induces programmed death-1-ligand 1(PD-L1) over-expression in hepatoma H22 cells via Erk /MAPK signaling pathway.
Qin X; Liu C; Zhou Y; Wang G
Cell Mol Biol (Noisy-le-grand); 2010 Sep; 56 Suppl():OL1366-72. PubMed ID: 20937224
[TBL] [Abstract][Full Text] [Related]
37. Co-inhibition of adenosine 2b receptor and programmed death-ligand 1 promotes the recruitment and cytotoxicity of natural killer cells in oral squamous cell carcinoma.
Wang B; Wang T; Yang C; Nan Z; Ai D; Wang X; Wang H; Qu X; Wei F
PeerJ; 2023; 11():e15922. PubMed ID: 37663280
[TBL] [Abstract][Full Text] [Related]
38. Sequential therapy with supercharged NK cells with either chemotherapy drug cisplatin or anti-PD-1 antibody decreases the tumor size and significantly enhances the NK function in Hu-BLT mice.
Kaur K; Chen PC; Ko MW; Mei A; Senjor E; Malarkannan S; Kos J; Jewett A
Front Immunol; 2023; 14():1132807. PubMed ID: 37197660
[TBL] [Abstract][Full Text] [Related]
39. Expanded human NK cells from lung cancer patients sensitize patients' PDL1-negative tumors to PD1-blockade therapy.
Poznanski SM; Ritchie TM; Fan IY; El-Sayes A; Portillo AL; Ben-Avi R; Rojas EA; Chew MV; Shargall Y; Ashkar AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479024
[TBL] [Abstract][Full Text] [Related]
40. Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers.
Moore EC; Cash HA; Caruso AM; Uppaluri R; Hodge JW; Van Waes C; Allen CT
Cancer Immunol Res; 2016 Jul; 4(7):611-20. PubMed ID: 27076449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
